The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Choosing efficacious treatment options for hepatocellular carcinoma
Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, discusses how the multitude of treatment options for hepatocellular carcinoma (HCC) blurs the line regarding the optimal first-line treatment. While many patients are receiving immunotherapies, other regimens also demonstrate promising activity. For instance, the CheckMate 9DW trial (NCT04039607) revealed that therapeutics such as sorafenib and lenvatinib achieved the highest-ever recorded median overall survival (OS). Atezolizumab plus bevacizumab is preferred in the first-line setting due to slightly better hazard ratios and statistically significant progression-free survival (PFS). However, immunotherapies may be chosen for patients with varices or other conditions. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Athenum Consulting; Boehringer Ingelheim; Cardinal Health; Exelixis; QED Therapeutics; Relay Therapeutics
Research Funding – Agios (Inst); ASLAN Pharmaceuticals (Inst); Basilea (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
